Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Nov 13, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies1, today announced the election of Dr. Allison...
-
Nov 13, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell,...
-
Nov 6, 2018- AutoSynVax™ (ASV™), AGEN2003 clinical trials data
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new data on several of its...
-
Nov 6, 2018- 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit >63% treated
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided a corporate update and reported...
-
Oct 31, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will release its third quarter 2018 financial...
-
Oct 20, 2018- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit1 in early analyses
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies2, presented updated clinical data on its lead...
-
Oct 9, 2018- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, will present new clinical data on its lead...
-
Sep 28, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, announced today that Dr. Jennifer Buell,...
-
Sep 21, 2018
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies1, today announced the closing of its...
-
Sep 17, 2018- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced today receipt of a cash...
